News - Oncology, Pricing

Filter

Current filters:

OncologyPricing

Popular Filters

1 to 25 of 146 results

UK’s NICE draft guidance backs Novartis’ Glivec for GISTs

UK’s NICE draft guidance backs Novartis’ Glivec for GISTs

27-06-2014

UK health care watchdog the National Institute for Health and Care Excellence (NICE) has issued new draft…

GlivecNovartisOncologyPharmaceuticalPricingRegulationUK

UK’s NICE says “Yes” to Bristol-Myers’ Yervoy

UK’s NICE says “Yes” to Bristol-Myers’ Yervoy

13-06-2014

People in England with advanced skin cancer should be able to receive ipilimumab as a first treatment…

Bristol-Myers SquibbOncologyPharmaceuticalPricingRegulationUKYervoy

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

Targeted therapies must show cost effectiveness to compete with biosimilars in Brazil and Mexico

10-06-2014

Certain targeted therapies enjoy extensive but incomplete coverage in Brazil and Mexico through complex…

BiosimilarsBrazilJohnson & JohnsonMabTheraMexicoOncologyPharmaceuticalPricingRocheVelcade

Hospira refutes high pricing of paclitaxel during drug shortage

Hospira refutes high pricing of paclitaxel during drug shortage

08-06-2014

The Canadian subsidiary of USA-based injectable generic drugs specialist Hospira has refuted press reports…

CanadaGenericsHospiraMarkets & MarketingOncologyPaclitaxelPricing

NICE draft guidance negative on Celgene’s Revlimid

20-05-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has today issued…

BiotechnologyCelgeneOncologyPricingRegulationRevlimidUK

Negative NICE draft guidance on Janssen’s Zytiga for prostate cancer

Negative NICE draft guidance on Janssen’s Zytiga for prostate cancer

14-05-2014

In draft guidance published this morning, the UK drugs watchdog the National Institute for Health and…

JanssenJohnson & JohnsonOncologyPharmaceuticalPricingRegulationUKZytiga

NICE issues positive recommendation for Astellas' Xtandi

NICE issues positive recommendation for Astellas' Xtandi

09-05-2014

In an about turn, UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has…

Astellas PharmaOncologyPharmaceuticalPricingRegulationUKXtandi

UK’s NICE rejects use of Roche’s Kadcyla for breast cancer on NHS

23-04-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today issued preliminary…

KadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheUK

UK NICE recommends Giotrif and Velcade, but says “no” to added use of Alimta

23-04-2014

People in England and Wales with lung cancer whose tumors test positive for a mutation will now have…

AlimtaBoehringer IngelheimEli LillyGiotrifJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

09-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlarvemurafenib

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

09-04-2014

Expensive treatments for broad patient populations are driving unprecedented growth in US spending on…

Anti-Arthritics/RheumaticsAnti-viralsMarkets & MarketingNorth AmericaOncologyPharmaceuticalPricingUSA

UK’s NICE reverses negative decision on Roche’s Tarceva for NSCLC

04-04-2014

Following a consultation period, the UK drug watchdog the National Institute for Health and Care Excellence…

Northern EuropeOncologyPharmaceuticalPricingRegulationRocheTarcevaUK

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera

03-04-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

NICE final guidance again rejects Sanofi’s Zaltrap for colorectal cancer

25-03-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE), today issued final guidance…

Northern EuropeOncologyPharmaceuticalPricingRegulationSanofiUKZaltrap

UK’s NICE unable to give the go ahead to new prostate cancer drug Xofigo

24-03-2014

The UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued new draft…

BayerNorthern EuropeOncologyPharmaceuticalPricingRegulationUKXofigo

UK NICE backs Janssen’s Velcade for multiple myeloma

UK NICE backs Janssen’s Velcade for multiple myeloma

21-03-2014

In new draft guidance published today, UK drugs watchdog the National Institute for Health and Care Excellence…

JanssenJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

Latest Australian PBS Listings include medicines for children

Latest Australian PBS Listings include medicines for children

19-03-2014

Ten new medicines to treat a range of illnesses from rare forms of cancer to skin conditions will be…

Anti-Arthritics/RheumaticsAsia-PacificAustraliaDermatologicalsDiabetesGastro-intestinalsHealthcareOncologyPharmaceuticalPricing

Added benefit for non-pre-treated Yervoy patients in advanced melanoma not proven, says IQWiG

Added benefit for non-pre-treated Yervoy patients in advanced melanoma not proven, says IQWiG

19-03-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) has re-assessed the added benefit…

Bristol-Myers SquibbGermanyNorthern EuropeOncologyPharmaceuticalPricingRegulationYervoy

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

17-03-2014

UK drugs watchdog the National Institute for Health and care Excellence (NICE) this morning issued new…

Boehringer IngelheimGiotrifNorthern EuropeOncologyPharmaceuticalPricingRegulationUK

NICE says better information needed on Celgene’s MM drug

NICE says better information needed on Celgene’s MM drug

14-03-2014

The UK drugs watchdog, the National Institute for Health and care Excellence (NICE) says that, based…

BiotechnologyCelgeneNorthern EuropeOncologyPricingRegulationRevlimidUK

Shifting payment dynamics for colorectal cancer and renal cell carcinoma treatment

Shifting payment dynamics for colorectal cancer and renal cell carcinoma treatment

06-03-2014

The increasing use of clinical pathway programs, accountable care organizations (ACOs) and bundled payments…

HealthcareOncologyPharmaceuticalPricing

UK’s NICE does U-turn on Pfizer’s Inlyta for advanced kidney cancer

UK’s NICE does U-turn on Pfizer’s Inlyta for advanced kidney cancer

04-03-2014

UK drug watchdog the National Institute for Health and Care Excellence (NICE) this morning published…

InlytaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheUK

Negative NICE appraisal for Eli Lilly’s Alimta as maintenance therapy

27-02-2014

UK health care guidance body the National Institute for Health and Care Excellence (NICE) has published…

AlimtaEli LillyNorthern EuropeOncologyPharmaceuticalPricingRegulationUK

1 to 25 of 146 results

Back to top